New IDH1 mutant inhibitors for treatment of acute myeloid leukemia-Reference-Cited by-同舟云学术

New IDH1 mutant inhibitors for treatment of acute myeloid leukemia

Published:2015-10-05 Issue:11 Volume:11 Page:878-886
ISSN:1552-4450
Container-title:Nature Chemical Biology
language:en
Short-container-title:Nat Chem Biol

Author:

Okoye-Okafor Ujunwa C,Bartholdy Boris,Cartier Jessy,Gao Enoch N,Pietrak Beth,Rendina Alan R,Rominger Cynthia,Quinn Chad,Smallwood Angela,Wiggall Kenneth J,Reif Alexander J,Schmidt Stanley J,Qi Hongwei,Zhao Huizhen^ORCID,Joberty Gerard,Faelth-Savitski Maria,Bantscheff Marcus,Drewes Gerard,Duraiswami Chaya,Brady Pat,Groy Arthur,Narayanagari Swathi-Rao,Antony-Debre Iléana,Mitchell Kelly,Wang Heng Rui,Kao Yun-Ruei,Christopeit Maximilian,Carvajal Luis,Barreyro Laura,Paietta Elisabeth,Makishima Hideki,Will Britta,Concha Nestor,Adams Nicholas D,Schwartz Benjamin,McCabe Michael T,Maciejewski Jaroslav,Verma Amit,Steidl Ulrich

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology

Link

http://www.nature.com/articles/nchembio.1930.pdf

Reference59 articles.

1. Rakheja, D., Konoplev, S., Medeiros, L.J. & Chen, W. IDH mutations in acute myeloid leukemia. Hum. Pathol. 43, 1541–1551 (2012).

2. Gupta, R. et al. Expanding the spectrum of IDH1 mutations in gliomas. Mod. Pathol. 26, 619–625 (2013).

3. Luchman, H.A. et al. An in vivo patient-derived model of endogenous IDH1-mutant glioma. Neuro-oncology 14, 184–191 (2012).

4. Ward, P.S. et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17, 225–234 (2010).

5. Shibata, T., Kokubu, A., Miyamoto, M., Sasajima, Y. & Yamazaki, N. Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. Am. J. Pathol. 178, 1395–1402 (2011).

Cited by 159 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ollier Disease, Acute Myeloid Leukemia, and Brain Glioma: IDH as the Common Denominator;Cancers;2024-09-11

2. Biostructural, biochemical and biophysical studies of mutant IDH1;Nature Communications;2024-09-09

3. Discovery of novel natural-product-derived mutant isocitrate dehydrogenases 1 inhibitors: Structure-based virtual screening, biological evaluation and structure-activity relationship study;European Journal of Medicinal Chemistry;2024-09

4. Development of Machine Learning-based QSAR Models for the Designing of Novel Anti-cancer Therapeutics Against Malignant Glioma;2024-08-19

5. The Tricarboxylic Acid Cycle Metabolites for Cancer: Friend or Enemy;Research;2024-01